100.19
-1.45 (-1.43%)
| Previous Close | 101.64 |
| Open | 101.60 |
| Volume | 111,685 |
| Avg. Volume (3M) | 121,475 |
| Market Cap | 1,933,085,952 |
| Price / Earnings (Forward) | 22.27 |
| Price / Sales | 16.79 |
| Price / Book | 3.91 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ligand Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.90 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 100.00% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 206.00 (HC Wainwright & Co., 105.61%) | Buy |
| Median | 187.50 (87.14%) | |
| Low | 175.00 (Benchmark, 74.67%) | Buy |
| Average | 189.00 (88.64%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 160.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 03 Sep 2025 | 190.00 (89.64%) | Buy | 166.54 |
| 30 Jul 2025 | 162.00 (61.69%) | Buy | 135.23 | |
| Benchmark | 02 Sep 2025 | 175.00 (74.67%) | Buy | 163.73 |
| HC Wainwright & Co. | 28 Aug 2025 | 206.00 (105.61%) | Buy | 159.96 |
| RBC Capital | 08 Aug 2025 | 185.00 (84.65%) | Buy | 150.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KOZARICH JOHN W | - | 163.73 | -467 | -76,462 |
| Aggregate Net Quantity | -467 | |||
| Aggregate Net Value ($) | -76,462 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 163.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Director | 02 Sep 2025 | Automatic sell (-) | 467 | 163.73 | 76,462 |
| Date | Type | Details |
|---|---|---|
| 19 Aug 2025 | Announcement | Ligand to Participate in September Investor Conferences |
| 14 Aug 2025 | Announcement | Ligand Announces Closing of Convertible Senior Notes Offering |
| 11 Aug 2025 | Announcement | Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 |
| 11 Aug 2025 | Announcement | Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering |
| 07 Aug 2025 | Announcement | Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance |
| 31 Jul 2025 | Announcement | Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed |
| 24 Jul 2025 | Announcement | Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 |
| 10 Jul 2025 | Announcement | Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ |
| 02 Jul 2025 | Announcement | Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |